Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CARM1/HDAC2 inhibitor
CARM1/HDAC2-IN-1 is a dual inhibitor targeting both CARM1 and HDAC2, exhibiting IC50 values of 3.71 nM and 4.07 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. CARM1/HDAC2-IN-1 is suitable for studies investigating the role of these epigenetic regulators in tumor biology and therapeutic strategies. -
PARG Inhibitor
PDD00017272 is a potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an EC50 of 4.8 nM. By inhibiting PARG activity, this compound promotes the accumulation of poly(ADP-ribose) (pADPr) on chromatin, thereby disrupting DNA damage repair and replication processes, leading to PARP1/2-dependent cytotoxicity. PDD00017272 is particularly valuable for research applications involving cancer models with DNA repair deficiencies, such as those characterized by BRCA mutations, and demonstrates enhanced efficacy in tumor cells exhibiting lower PARG expression. -
PARG Inhibitor
PDD00017238 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), demonstrating EC50 values of 40 nM in biochemical assays and 55 nM in cellular assays. This compound effectively disrupts the enzymatic activity of PARG, leading to the accumulation of poly(ADP-ribose) chains and influencing DNA repair mechanisms. PDD00017238 is useful for studying the role of PARG in cellular processes, particularly in the context of DNA damage response and potential therapeutic strategies in oncology. -
PARG Inhibitor
PDD00031705 is a benzimidazolone-based inhibitor targeting poly (ADP-ribose) glycohydrolase (PARG). This compound exhibits potential in regulating poly (ADP-ribose) metabolism, which plays a critical role in DNA damage repair and cell signaling. PDD00031705 is useful in research applications focused on understanding the physiological and pathological roles of PARG in cellular processes and its implications in cancer biology. -
PARG Inhibitor
COH34 analog 1 is an oxidized derivative of the potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor, COH34. This compound specifically targets PARG, leading to the inhibition of poly(ADP-ribose) metabolism. Its role in PARG inhibition makes it a valuable tool for studying cellular processes involved in DNA repair, cellular stress responses, and other related pathways in chemical biology and therapeutic research. -
PARG Inhibitor
PARG-IN-7 is a potent inhibitor of Poly ADP-ribose glycohydrolase (PARG), exhibiting an IC50 of less than 0.1 μM. This compound significantly reduces cell viability in HCC1806 cells with XRCC1 knockdown, demonstrating an IC50 of less than 1 μM. PARG-IN-7 is a valuable tool for cancer research, particularly in studies investigating the role of PARP-related pathways in tumor biology. -
PARG Inhibitor
PDD00031704 is an inhibitor of poly (ADP-ribose) glycohydrolase (PARG), demonstrated to have an IC50 value greater than 60 µM. It plays a crucial role in the regulation of ADP-ribosylation, impacting cellular processes such as DNA repair and apoptosis. This compound is valuable for research applications focused on cancer biology, cellular stress responses, and modulation of DNA damage pathways. -
PARG Inhibitor
FORX-428 is a selective and orally bioavailable inhibitor of Poly (ADP-ribose) glycohydrolase (PARG), which targets the catalytic domain of human PARG to effectively inhibit its enzymatic activity. By promoting the accumulation of PAR chains, FORX-428 activates DNA damage response pathways and replication stress responses. This compound demonstrates selective antiproliferative effects across a range of cancer cell lines, including those derived from breast, ovarian, and gastric cancers, making it a valuable tool for cancer research and therapeutic studies. -
PARP-1 Inhibitor
PARP-1-IN-32 is a potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1). This compound is utilized in cancer research to investigate the mechanisms of DNA repair and cellular response to genotoxic stress. Its ability to selectively inhibit PARP-1 makes it a valuable tool for studying the role of this enzyme in tumor biology and therapeutic resistance. -
SIRT6 Inhibitor
SIRT6-IN-6 is a selective inhibitor of SIRT6, demonstrating a potent IC50 of 4.93 μM and a Ki of approximately 10 μM. This compound shows significant selectivity against other histone deacetylases, including SIRT1-3 and HDAC1-11. Research findings indicate that SIRT6-IN-6 effectively elevates the expression of the glucose transporter GLUT-1, which contributes to the reduction of blood glucose levels in mouse models of type 2 diabetes. This reagent is valuable for studies focused on the mechanistic pathways associated with type 2 diabetes and metabolic regulation. -
Sirtuin Inhibitor
MC3482 is a selective inhibitor of sirtuin 5 (SIRT5), known for its role in mitochondrial metabolism and deacylation processes. This compound effectively modulates SIRT5 activity, making it valuable for studies examining the implications of SIRT5 in cellular energy regulation and metabolic disorders. Its use in research can contribute to understanding SIRT5's role in various physiological and pathological conditions, including cancer and neurodegeneration. -
SIRT5 Inhibitor
MC3138 is a selective SIRT5 inhibitor, demonstrating notable antitumor activity in human pancreatic ductal adenocarcinoma (PDAC) cells, with IC50 values ranging from 25.4 to 236.9 μM. In preclinical studies, MC3138 enhances the efficacy of Gemcitabine, significantly inhibiting tumor growth in murine models. This compound is valuable for research into targeted cancer therapies and the modulation of metabolic pathways related to SIRT5 activity. -
SIRT5 Inhibitor
Et-29 is a potent inhibitor of SIRT5, with a reported Ki value of 40 nM, demonstrating selectivity for this target. By modulating the activity of SIRT5, Et-29 plays a significant role in the study of metabolic processes and post-translational modifications. This reagent is ideal for research applications focused on the regulation of cellular metabolism and potential therapeutic strategies in metabolic diseases. -
SIRT6 Inhibitor
SIRT6-IN-2 is a selective and competitive inhibitor of SIRT6, exhibiting an IC50 of 34 μM. This compound enhances the acetylation of H3K9 and promotes glucose uptake in cultured cells. Additionally, SIRT6-IN-2 demonstrates the ability to reduce T cell proliferation, showcasing its immunosuppressive properties and potential chemosensitizing effects. Research applications include the study of metabolic regulation and immune response modulation. -
SIRT Inhibitor
SIRT-IN-3 is a selective inhibitor of SIRT1 with an IC50 of 17 μM. It demonstrates approximately 4-fold selectivity over SIRT2 and 14-fold selectivity over SIRT3, exhibiting IC50 values of 74 μM and 235 μM, respectively, for these isoforms. This compound is valuable for research applications investigating the role of SIRT1 in cellular processes, including aging, metabolism, and gene regulation. -
SIRT5 Inhibitor
SIRT5 Inhibitor 3 is a potent and competitive inhibitor of SIRT5, exhibiting an IC50 value of 5.9 μM. This compound effectively inhibits the desuccinylation activity of SIRT5, making it a valuable tool for studying the enzyme's role in various biological processes. SIRT5 Inhibitor 3 is applicable in research focused on cancer and neurodegenerative diseases, providing insights into potential therapeutic strategies. -
SIRT1 Inhibitor
SIRT1-IN-4 is a selective SIRT1 inhibitor that demonstrates an IC50 of 10.04 μM. This compound is utilized in research focused on cancer biology, providing valuable insights into the role of SIRT1 in tumorigenesis and potential therapeutic approaches. Further studies may explore its utility in modulating cellular processes regulated by SIRT1. -
SIRT1 Inhibitor
(S)-Selisistat is a selective inhibitor of SIRT1, demonstrating an IC50 value of 98 nM. This compound effectively modulates the activity of the sirtuin family of proteins, which are implicated in various cellular processes, including metabolism and aging. (S)-Selisistat is valuable for research exploring the role of SIRT1 in age-related diseases and metabolic disorders, making it a crucial tool for investigating therapeutic strategies in these areas. -
SIRT3 Inhibitor
SIRT3-IN-1 is a potent Sirtuin 3 (SIRT3) inhibitor with an IC50 value of 0.043 μM. This compound selectively inhibits SIRT3, making it a valuable tool for studying the role of SIRT3 in acute myeloid leukemia (AML) and other related conditions. Its specific action on SIRT3 allows for targeted investigations into cellular metabolism, oxidative stress response, and potential therapeutic strategies in AML research. -
SIRT7 Inhibitor
YZL-51N is a selective inhibitor of SIRT7, with an IC50 value of 12.71 μM. By occupying the NAD+ binding pocket, YZL-51N inhibits SIRT7 enzyme activity, thereby compromising DNA damage repair mechanisms and reducing cancer cell viability. Its demonstrated anti-tumor activity makes YZL-51N a valuable tool for cancer research applications. -
SIRT1 Inhibitor
SIRT1-IN-3 is a selective inhibitor of SIRT1, exhibiting an IC50 value of 4.2 μM. This compound effectively modulates SIRT1 activity, making it a valuable tool for studies investigating the role of SIRT1 in various biological processes. Research applications include the exploration of SIRT1's involvement in metabolism, aging, and stress response pathways. -
SIRT1 Inhibitor
SIRT1-IN-2 is a potent and selective inhibitor of SIRT1 (silent information regulator 1), demonstrating an IC50 value of 1.6 μM. This compound plays a critical role in research focused on understanding the regulation of cellular metabolism, aging, and stress response pathways. Its specific inhibition of SIRT1 makes it a valuable tool for studying related biological processes and therapeutic interventions. -
Sirt2 Inhibitor
Sirt2-IN-2 is a selective inhibitor of the Sirtuin 2 (Sirt2) enzyme, exhibiting an IC50 of 0.118 μM. This compound is instrumental in research aimed at studying the role of Sirt2 in cellular processes and its implications in neurodegenerative diseases. Its use facilitates investigations into the potential therapeutic effects of Sirt2 modulation. -
Sirt2 inhibitor
SirReal-1 is a selective inhibitor of SIRT2, with an IC50 of 3.7 μM. This compound is utilized in research to investigate the biological role of SIRT2 in various cellular processes and its potential implications in cancer and neurodegenerative diseases. SirReal-1 serves as a valuable tool for elucidating the mechanisms of SIRT2-related signaling pathways. -
Sirtuin Inhibitor
Sirtuin-1 Inhibitor 1 is a selective inhibitor of Sirtuin-1, a key regulator in metabolic processes and cellular aging. This compound demonstrates potential in the study of obesity-related diabetes and age-associated diseases by modulating the activity of Sirtuin-1. Its application in research can enhance understanding of metabolic disorders and the molecular underpinnings of aging. -
SIRT2 Inhibitor
SIRT2-IN-11 is a selective inhibitor of the SIRT2 enzyme, exhibiting an IC50 value of 18.5 μM. This compound induces apoptosis in a p53-dependent manner, leading to the upregulation of CDKN1A, PUMA, and NOXA, along with increased p53 acetylation. SIRT2-IN-11 is a valuable tool for investigating p53-related cancer mechanisms and therapeutic strategies. -
SIRT2 Inhibitor
AC-93253 is a potent and selective inhibitor of SIRT2, achieving an IC50 value of 6 μM. This compound is instrumental in investigating the role of SIRT2 in tumor biology and may aid in the development of therapeutic strategies targeting SIRT2-related pathways in cancer research. Its specificity enhances the potential for targeted studies in cellular and molecular biology. -
SIRT2 Inhibitor
MIND4-19 is a selective inhibitor of SIRT2, demonstrating an IC50 value of 7.0 μM. This compound is primarily utilized in research related to Huntington's disease, offering insights into the therapeutic potential of SIRT2 modulation in neurodegenerative disorders. Its potency and target specificity make MIND4-19 a valuable tool for studying the role of SIRT2 in disease mechanisms and potential treatments. -
Sirtuin Inhibitor
Z26395438 is a potent inhibitor of Sirtuin-1, exhibiting an IC50 value of 1.6 μM. This compound is instrumental in research involving metabolic regulation, aging, and cellular stress responses. Its ability to modulate Sirtuin activity highlights its potential applications in studying various physiological and pathological processes. -
SIRT1 Inhibitor
CHIC35 is a selective inhibitor of SIRT1, exhibiting an IC50 of 0.124 μM. It demonstrates preferential inhibition of SIRT1 over SIRT2 (IC50=2.8 μM) and SIRT3 (IC50>100 μM). This compound is recognized for its anti-inflammatory properties and is applicable in research related to CHARGE syndrome. -
SIRT Inhibitor
SIRT1/2/3-IN-2 is a potent inhibitor of SIRT1, SIRT2, and SIRT3, exhibiting inhibition rates of 27%, 72%, and 71% respectively at a concentration of 200 μM. This compound is instrumental in studying the roles of sirtuins in various biological processes, particularly their involvement in cancer biology. SIRT3, known as a potential tumor suppressor or promoter, has been linked to lymph node-positive breast cancer and oral squamous cell carcinoma, making SIRT1/2/3-IN-2 valuable for cancer research applications. -
SIRT2 Inhibitor
SIRT2-IN-10 is a selective inhibitor of SIRT2, exhibiting an inhibitory concentration (IC50) of 1.3 μM. This compound is instrumental in studying its role in cancer pathology and neurodegenerative disorders, enabling research into potential therapeutic applications. Its ability to modulate SIRT2 activity makes it a valuable tool for investigating cellular mechanisms and disease progression. -
SIRT7 Inhibitor
Epigenetic factor-IN-1 is a selective SIRT7 inhibitor that plays a crucial role in modulating epigenetic regulation. It demonstrates a strong binding affinity for the SIRT7 protein, making it an important tool for exploring the mechanisms of epigenetic modifications. This compound is particularly relevant for liver cancer research, providing insights into the role of SIRT7 in cancer biology and therapeutic development. -
sirtuin SirT2 Inhibitor
Tenovin-D3 hydrochloride is a selective inhibitor of the sirtuin SirT2, which plays a crucial role in cellular regulation. This compound has been shown to enhance the expression of p21 (CDKN1A) independently of the p53 pathway. It is suitable for research applications focused on aging, cancer biology, and the modulation of cellular stress responses to explore the therapeutic potential of sirtuin inhibition. -
SIRT2 Inhibitor
Sirt2-IN-6 is a potent and selective inhibitor of SIRT2, exhibiting an IC50 of 0.815 μM. It demonstrates significant biological activity in modulating SIRT2-related pathways and is valuable for cancer research applications. This compound facilitates the exploration of SIRT2's role in oncogenesis and therapeutic development. -
SIRT1/2 Inhibitor
hsa62 is a dual inhibitor targeting SIRT1 and SIRT2, demonstrating IC50 values of 1.3 μM and 5.5 μM, respectively. This compound effectively modulates the activity of sirtuins, enzymes involved in various cellular processes, including metabolism and aging. hsa62 is suitable for research investigating the role of sirtuins in cellular regulation, disease models, and therapeutic applications. -
SIRT5 Inhibitor
SIRT5 Inhibitor 6 is a selective and potent inhibitor of SIRT5 that functions through a substrate-competitive mechanism, demonstrating an IC50 value of 3.0 μM. This compound shows promise in therapeutic applications for septic acute kidney injury (AKI) in vivo, making it a valuable tool for research in kidney health and related pathologies. -
SIRT1/SIRT2 Inhibitor
Guttiferone G is a selective inhibitor of the human SIRT1 and SIRT2 deacetylases, exhibiting IC50 values of 9 μM and 22 μM, respectively. This compound demonstrates weak cytotoxicity in the A2780 human ovarian cancer cell line, with an IC50 of 8.0 μg/mL. Guttiferone G is derived from Garcinia macrophylla and may serve as a valuable tool in research studies exploring SIRT1 and SIRT2 modulation in cellular processes. -
SIRT5 Inhibitor
SIRT5 inhibitor 5 is a potent inhibitor of the SIRT5 enzyme, exhibiting an IC50 value of 0.21 µM. This compound functions as a substrate-competitive inhibitor, specifically not occupying the NAD+-binding pocket, thereby modulating SIRT5 activity. SIRT5 inhibitor 5 is valuable in research focused on elucidating the role of SIRT5 in metabolic pathways and providing insights into its potential implications in various diseases. -
SIRT5 Inhibitor
SIRT5 Inhibitor 4 is a selective inhibitor of the SIRT5 enzyme, demonstrating an IC50 value of 26.4 μM. This compound exhibits minimal activity against other SIRT subtypes, with an IC50 greater than 400 μM, underscoring its specificity. It serves as a valuable tool for investigating the biological roles of SIRT5 in metabolic regulation and related pathways. Research applications include studying SIRT5's involvement in cellular processes and potential therapeutic targets in metabolic disorders. -
SIRT2 Inhibitor
AGK7 is a selective inhibitor of sirtuin 2 (SIRT2), demonstrating significant neuroprotective effects in the context of Parkinson's disease. This compound has been shown to alleviate alpha-synuclein toxicity and improve inclusion morphology in cellular models. In addition, AGK7 effectively protects against dopaminergic cell death in both in vitro studies and Drosophila models, making it a valuable tool for researching neurodegenerative disorders. -
SIRT3 Inhibitor
SIRT-IN-5 is a selective inhibitor of SIRT3, demonstrating an IC50 value of 2.88 μM. This compound has been shown to promote the differentiation of multiple myeloma cells, facilitating increased expression of differentiation antigens such as CD49e, as well as enhancement of human immunoglobulin light chains λ and κ. SIRT-IN-5 is a valuable tool in research focused on the modulation of cellular differentiation processes in hematological malignancies. -
SIRT1/2 Inhibitor
Sirtuin-IN-1 is a selective inhibitor of SIRT1 and SIRT2, with IC50 values of 6.2 μM and 4.2 μM, respectively. This compound has been shown to induce G1 phase cell cycle arrest, demonstrating its potential as an anti-cancer agent. Sirtuin-IN-1 is particularly effective against glioma, making it a valuable tool for research into cancer therapeutics and the exploration of sirtuin-related biological pathways. -
SIRT1 Inhibitor
Sirtuin Modulator 4 is a selective SIRT1 inhibitor, demonstrating an EC50 value of 51-100 μM. This compound plays a critical role in modulating cellular pathways associated with lifespan extension and offers potential in researching a variety of conditions, including diabetes, obesity, neurodegenerative diseases, cardiovascular disorders, inflammation, and cancer. Its ability to inhibit SIRT1 makes it a valuable tool for studying the therapeutic implications of sirtuin regulation in metabolic and age-related diseases. -
SIRT2 Inhibitor
SIRT2-IN-14 is a selective inhibitor of SIRT2, demonstrating an IC50 value of 0.196 μM. This compound effectively modulates SIRT2 activity, making it a valuable tool for studying the role of SIRT2 in various biological pathways. Research applications may include investigations into neurodegenerative diseases, cancer biology, and cellular metabolism, providing insights into the therapeutic potential of targeting SIRT2. -
SIRT5 Inhibitor
SIRT5 inhibitor 2 is a selective inhibitor of the SIRT5 enzyme, exhibiting an IC50 value of 2.3 μM. It effectively inhibits SIRT5-dependent desuccinylation processes, making it a valuable tool for investigating the roles of SIRT5 in various biological contexts. This compound is suitable for research applications focusing on cancer biology and neurodegenerative diseases, aiding in the exploration of therapeutic strategies targeting SIRT5 activity. -
SIRT1 Inhibitor
ZINC08792355 is a selective SIRT1 inhibitor that plays a crucial role in the regulation of cellular processes associated with aging, metabolic disorders, and oncogenesis. This compound facilitates the exploration of SIRT1-related pathways in research on age-related diseases, diabetes, and cancer, making it a valuable tool for investigators studying these important biological phenomena. -
SIRT2 Inhibitor
SR94 is a selective SIRT2 inhibitor that features a unique six-membered ring structure with variable R2 substituents. This compound demonstrates potential in the investigation of cancer, ischemia-reperfusion injury, and neurodegenerative diseases. Its targeted inhibition of SIRT2 makes it a valuable tool for understanding the role of this enzyme in various biological processes and disease states. -
SIRT5 Inhibitor
SIRT5 Inhibitor 7 is a selective substrate-competitive inhibitor targeting SIRT5, known for its anti-inflammatory properties. This compound effectively regulates protein succinylation and reduces the release of pro-inflammatory cytokines, offering potential renal protective effects. SIRT5 Inhibitor 7 demonstrates notable in vivo efficacy in mouse models of acute kidney injury induced by lipopolysaccharide (LPS) and cecal ligation/perforation (CLP), making it a valuable tool for researching sepsis-related kidney damage. -
SIRT1 Inhibitor
ZINC08792229 is a potent inhibitor of SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase playing a crucial role in cellular regulation. This compound exhibits significant biological activity that may contribute to research on SIRT1-related diseases, including aging, diabetes, and cancer. It serves as a valuable tool for exploring the therapeutic potential of targeting SIRT1 in various pathological conditions.
